Cardiorenalmetabolic

Metallomic correlations suggest environmental and metabolic metals act together to accelerate renal damage.

Remote monitoring and algorithm-based tools help pharmacists balance complex workloads in value-based care, says Lindsey Valenzuela, PharmD.

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on cardiotoxicity, explains Rakendu Rajendran, MBBS.

Adults with diabetes were 24% less likely to visit an emergency department in 2021 than in 2019.

Lindsey Valenzuela, PharmD, explains how value-based models empower a single pharmacist to manage multiple layers of these disease states.

A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial disparities and high costs.

Lindsey Valenzuela, PharmD, explains how pharmacists can prevent drug interactions and improve coordination for women with arrhythmia and chronic disease.

Lindsey Valenzuela, PharmD, explains how cost, coverage gaps, and tech literacy hinder women’s access to early arrhythmia detection tools.

Lindsey Valenzuela, PharmD, explains how atypical symptoms, research gaps, and care inequities delay arrhythmia detection in women.

The class of diabetes drug has a protective effect on the kidneys for reasons beyond glucose control.

A CCS report found that pharmacists lack time for diabetes education as workloads rise, worsening disparities and threatening adherence.

Primary aldosteronism is often overlooked in hypertension. Educating providers and utilizing tools can enhance screening and treatment effectiveness, emphasizes Vivek Bhalla, MD, Stanford.

Electronic health record (EHR)–based “e-phenotypes” combining lab data, coding, and AI could dramatically improve early detection and management of chronic kidney disease.

Treating constipation with lubiprostone may confer renal benefits in chronic kidney disease by modulating microbiome-driven pathways.

Only a fraction of countries in the world have designated chronic kidney disease as a health priority.

Research reveals that patients with both rheumatoid arthritis and MASH cirrhosis face significantly higher cardiovascular risks.

New findings reveal sotatercept's significant benefits for right ventricular function and tricuspid regurgitation in pulmonary arterial hypertension.

Data reveal a growing burden of early-onset type 2 diabetes, highlighting disparities and increased cardiometabolic risk

Cardiologists, nephrologists, and payers met in Scottsdale, Arizona, on August 26, 2025, to share insights on how team members can work together, empowered by data, to achieve value-based management of cardio-renal-metabolic syndrome.

Experts in cardiometabolic conditions gathered in Aurora, Colorado, on August 19, 2025, to discuss the methods available to prevent cardiovascular events.

From 2017 to 2023, women were especially underrepresented in trials in arrhythmia, coronary heart disease, acute coronary syndrome, and heart failure.

As the prevalence of both chronic kidney disease (CKD) and heart failure (HF) increases, therapies targeting shared pathways are one of the most promising strategies to alter the trajectory of these diseases.

The drug lowered inflammation, oxidative stress, and endothelial injury markers in women with INOCA and coronary microvascular dysfunction.

A new joint guideline from the American Heart Association and the American College of Cardiology emphasizes early treatment, close perinatal blood pressure monitoring, and incorporating the PREVENT risk calculator to personalize care.

Metabolic syndrome severity is a meaningful marker of chronic kidney disease risk even when patients do not have other major risk factors.